HomeClinical TopicsFDA approves biosimilar for adults with non-Hodgkin’s lymphoma

FDA approves biosimilar for adults with non-Hodgkin’s lymphoma

Author(s):

On Nov. 28, the FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

Read more via U.S. Food & Drug Administration.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...